Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Description

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. In part 3 (dose expansion), participants will receive the RP2D oral dose of ABBV-525. The estimated duration of the study is up to 64 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions

Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. In part 3 (dose expansion), participants will receive the RP2D oral dose of ABBV-525. The estimated duration of the study is up to 64 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Condition
Diffuse Large B-Cell Lymphoma
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California Los Angeles /ID# 246357, Los Angeles, California, United States, 90095

New Haven

Yale University School of Medicine /ID# 259081, New Haven, Connecticut, United States, 06510

Miami Beach

Mount Sinai Medical Center-Miami Beach /ID# 248251, Miami Beach, Florida, United States, 33140-2948

Fort Wayne

Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113, Fort Wayne, Indiana, United States, 46804

Indianapolis

Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 259872, Indianapolis, Indiana, United States, 46202-5116

New Orleans

Tulane Cancer Center Clinic /ID# 249586, New Orleans, Louisiana, United States, 70112

Grand Rapids

START Midwest /ID# 252359, Grand Rapids, Michigan, United States, 49546

New York

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 245459, New York, New York, United States, 10065-6007

Charlotte

Levine Cancer Institute /ID# 246363, Charlotte, North Carolina, United States, 28204

Cincinnati

University Of Cincinnati Medical Center /ID# 262288, Cincinnati, Ohio, United States, 45219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Dose Escalation (Part 1) Only: Participants with a documented diagnosis of one of the following third line or later of treatment (3L)+ mature B-cell malignancies, from the World Health Organization (WHO)-defined histologies as defined in the protocol.
  • * Dose Optimization (Part 2) Only: Participants with documented diagnosis of chronic lymphocytic leukemia (CLL) who are 3L+, +/- cysteine-to-serine point mutation at residue 481 of BTK-domain active site (C481S with histology based on WHO criteria, with measurable disease requiring treatment as defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
  • * Dose Expansion (Part 3) Only: Participants with documented diagnosis of non-germinal center B cell (GCB) Diffuse large B-cell lymphoma (DLBCL) who are 3L+ chimeric antigen receptor T-cells (CAR-T)/Hematopoietic cell transplant (HCT) relapsed/refractory (R/R) and/or ineligible with histology based on WHO criteria, with measurable disease requiring treatment.
  • * Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
  • * Participant has a life expectancy \>= 12 weeks.
  • * Adequate hematological and hepatic function as defined in the protocol.
  • * Must have archival or freshly collected tumor tissue for correlative studies before study enrollment.
  • * Participants with prior central nervous system (CNS) disease that has been effectively treated may be eligible.
  • * Participants with resolved coronavirus disease 2019 (COVID-19) infection are eligible.
  • * Known active CNS disease, or primary CNS lymphoma.
  • * Known bleeding disorders.
  • * Known history of stroke or intracranial hemorrhage within 12 months prior to first dose of study treatment.
  • * Uncontrolled active systemic infection, or active cytomegalovirus infection.
  • * Active hepatitis B or C infection.
  • * Known history of human immunodeficiency virus (HIV).
  • * Known active COVID-19 infection. Participant must not have signs/symptoms associated with COVID-19 infection or known exposure to a confirmed case of COVID-19 infection during screening. If participant has signs/symptoms suggestive of COVID-19 infection, the participant must have a negative molecular (eg, polymerase chain reaction) test or 3 negative antigen test results at least 24 hours apart.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AbbVie,

ABBVIE INC., STUDY_DIRECTOR, AbbVie

Study Record Dates

2027-06